324 related articles for article (PubMed ID: 27272086)
1. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
5. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
6. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
Werner K; Kobayashi TT
Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
[TBL] [Abstract][Full Text] [Related]
7. Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction.
Gillihan R; Nguyen T; Fischer R; Rajpara A; Aires D
JAMA Dermatol; 2015 Oct; 151(10):1136-7. PubMed ID: 26083825
[No Abstract] [Full Text] [Related]
8. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
9. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.
Johnson AW; Johnson SM
Dermatol Ther (Heidelb); 2015 Sep; 5(3):171-81. PubMed ID: 26112098
[TBL] [Abstract][Full Text] [Related]
10. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
Gerber PA
Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630
[No Abstract] [Full Text] [Related]
11. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
Oon HH; Lim ZV
Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
13. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
Routt ET; Levitt JO
J Am Acad Dermatol; 2014 Feb; 70(2):e37-8. PubMed ID: 24438976
[No Abstract] [Full Text] [Related]
14. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea.
Hofmann MA; Kokolakis G
J Cosmet Laser Ther; 2017 Aug; 19(4):222-224. PubMed ID: 28139145
[TBL] [Abstract][Full Text] [Related]
15. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
El-Domyati M; Rezk AF; Nasif G; Abdelhameed SS; Medhat W
Int J Dermatol; 2023 Jul; 62(7):888-894. PubMed ID: 37212604
[TBL] [Abstract][Full Text] [Related]
16. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
[TBL] [Abstract][Full Text] [Related]
18. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
Micali G; Dall'Oglio F; Verzì AE; Luppino I; Bhatt K; Lacarrubba F
Lasers Med Sci; 2018 Aug; 33(6):1397-1400. PubMed ID: 28889348
[TBL] [Abstract][Full Text] [Related]
19. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
[TBL] [Abstract][Full Text] [Related]
20. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
